Attribute preferences associated with gonadotropin-releasing hormone agonists/antagonists among women with endometriosis in the United States
Relieving the three types of endometriosis pain and reducing cost are the most important considerations for women when selecting GnRH agonist/antagonist treatment. Women with endometriosis strongly prefer a medication that can be safely taken for longer periods of time, takes effect within a few menstrual cycles, and can reduce endometriosis-related fatigue. Findings can inform discussions between patients and healthcare providers to better align endometriosis treatment decision-making with patients' individual needs and preferences.
Authors
- Kathleen Marie Beusterien (ORCID: https://orcid.org/0000-0001-7786-5422)
- Brett Hauber (ORCID: https://orcid.org/0000-0003-3129-7268)
- Martine C. Maculaitis (ORCID: https://orcid.org/0000-0001-8388-5315)
- Nicole T. Ansani
- Paul Cislo
- Ruth Kim
- Elke Hunsche (ORCID: https://orcid.org/0000-0002-5611-0554)
Institutions
- Oracle (United States) (US)
- Pfizer (United States) (US)
- Amgen (Switzerland) (CH)
- Statistical Research (United States) (US)
Publication Details
- Journal
- Women s Health
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1177/17455057251331700
- Primary Topic
- Endometriosis Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00